menu
    • menu
    [{"orgOrder":0,"company":"Ora, Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Stuart Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vezocolmitide","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Ora, Inc

    Menu

    Ora, Inc

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ora, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vezocolmitide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Stuart Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Stuart Therapeutics Announces First Patient, First Visit in Its Phase 3 Clinical Trial of Vezocolmitide for Dr...

                            Details : ST-100 (vezocolmitide) is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen. It is under phase 3 clinical development for the treatment of Dry Eye D...

                            Brand Name : ST-100

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 29, 2023

                            Lead Product(s) : Vezocolmitide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Stuart Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ora, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : OcuMension Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Okuvision's Low-Concentration Atropine OT-101 has been Approved by the US FDA to Carry out The Pediatric Resea...

                            Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.

                            Brand Name : OT-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 22, 2021

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : OcuMension Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ora, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : OcuMension Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Okvision Low Concentration Atropine Sulfate Eye Drops OT-101 Completed the First Subject Enrollment and Plans ...

                            Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.

                            Brand Name : OT-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 07, 2021

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : OcuMension Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ora, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : OcuMension Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Okuvision Low Concentration Atropine Sulfate Eye Drops Ot-101 was Approved by the US FDA For Phase III Clinica...

                            Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.

                            Brand Name : OT-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 22, 2021

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : OcuMension Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth